Immunofoco secures nearly RMB 200 million in Pre-IPO round to advance solid tumor and in vivo CAR‑T dual‑engine strategy

Recently, Immunofoco, a globally leading innovative cell therapy company, completed a Pre-IPO round of financing amounting to nearly RMB 200 million. This round was led by Gaorong Ventures and Jifeng Ventures, with participation from Shenzhen Angel FOF and Mingdao Investment. Existing shareholder IN Capital continued to increase its investment, and China Renaissance served as the exclusive financial advisor.

Including this round, Immunofoco has completed three financing rounds in less than a year, with a total accumulated financing amount exceeding RMB 600 million. Immunofoco has attracted numerous internationally renowned biomedical funds, insurance funds, and industrial funds, including Vivo Capital, Taiping Healthcare Fund, Fosun Health Capital, and Green Pine Capital Partners. This reflects investors' strong attention to and recognition of Immunofoco's CAR-T technology platform for solid tumors, its clinical data and progress, its in-vivo CAR-T technology positioning, and its management team.

Since its establishment, Immunofoco has focused on addressing clinical needs in the field of solid tumor treatment. Targeting the current pain points of CAR-T therapies for solid tumors, Immunofoco has built cutting-edge next-generation CAR-T technology platforms, including SNR, Peri Cruiser®, T-Booster, and SolidGuard. These platforms are designed to overcome challenges such as antigen heterogeneity, on-target off-tumor toxicity, T cell exhaustion, insufficient tumor tissue infiltration, and the immunosuppressive tumor microenvironment, providing technical support for the continuous expansion of its solid tumor CAR-T product pipeline. Simultaneously, to address the pain points of long production cycles and high costs associated with autologous CAR-T products, Immunofoco has developed the FOCO CAR manufacturing process, effectively shortening the production cycle and significantly reducing production costs, thereby improving the accessibility of autologous CAR-T products.

According to Frost & Sullivan data, Immunofoco's potential best-in-class candidate product, IMC002 (targeting CLDN18.2), is the second fastest-progressing solid tumor CAR-T therapy globally in clinical development. In the Phase I/IIa clinical trial, the RP2D dose group achieved a median progression-free survival of 6.9 months and a median overall survival of 18.2 months in third-line and beyond gastric cancer patients. One patient achieved complete response according to RECIST 1.1 criteria, with all tumor tissue completely disappearing 36 weeks after IMC002 infusion. As of the latest follow-up assessment (January 2026), the patient has maintained complete response for over 70 weeks without receiving any additional anti-tumor therapy. The pivotal Phase III clinical trial for advanced gastric cancer was initiated in the third quarter of 2025, and patient enrollment is currently underway. IMC001 (targeting EpCAM) is the world's only EpCAM CAR-T therapy that has simultaneously received Investigational New Drug approvals from both the U.S. FDA and China's NMPA and has entered the Phase I clinical stage. Multiple product pipelines are steadily advancing, with continuous accumulation of clinical and research and development data.

Building upon the steady advancement of its autologous CAR-T programs in clinical development, Immunofoco has made a forward-looking investment in cutting-edge in vivo CAR-T technology, establishing its proprietary iMAGIC in vivo CAR-T platform. This platform is based on a novel lentiviral vector capable of specifically recognizing and transducing T cells in situ. It utilizes an AI-optimized, detargeted MxV glycoprotein combined with a proprietary T-cell targeting module to achieve selective T-cell activation and transduction in vivo, while minimizing the risk of off-target gene delivery to non-T cells.

The iMAGIC platform has been validated across multiple preclinical models and programs, including projects targeting CD19 (IMV101), BCMA (IMV102), and CLDN18.2 (IMV103). Some of the related research findings have been selected for presentation at the American Society of Gene and Cell Therapy Annual Meeting, ASGCT's Breakthroughs in Targeted In Vivo Gene Editing, and the 67th American Society of Hematology Annual Meeting, showcased in poster format.